This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Guotai Haitong Sticks to Its Buy Rating for Wuxi Biologics (Cayman) (WXIBF)

Tipranks - Tipranks - Wed Jun 10, 12:28AM CDT

In a report released yesterday, from Guotai Haitong maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$54.49. The company’s shares closed last Wednesday at HK$30.38.

Introducing TipRanks MCP for Agents

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Wuxi Biologics (Cayman) with a HK$45.30 average price target, implying a 49.10% upside from current levels. In a report released on June 1, Morgan Stanley also maintained a Buy rating on the stock with a HK$50.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Wuxi Biologics (Cayman)’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of HK$11.84 billion and a net profit of HK$2.57 billion. In comparison, last year the company earned a revenue of HK$10.1 billion and had a net profit of HK$1.86 billion

Read More on WXIBF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).